Minimal clinically important difference and Edmonton Symptom Assessment Scale

Author： Johnson Miriam J. Currow David C.

E-ISSN： 1097-0142|122|1|158-159

ISSN： 0008-543X

Source： Cancer, Vol.122, Iss.1, 2016-01, pp. : 158-159

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Reply to minimal clinically important difference and Edmonton Symptom Assessment Scale

By Hui David Bruera Eduardo

Cancer, Vol. 122, Iss. 1, 2016-01 ,pp. : 159-160

Blackwell Publishing

Access to resources Recommend Favorite

Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study

Cancer, Vol. 121, Iss. 17, 2015-09 ,pp. : 3027-3035

Blackwell Publishing

Access to resources Recommend Favorite

Evaluating Minimal Clinically Important Differences for the Acne-Specific Quality of Life Questionnaire

By McLeod L.D.

PharmacoEconomics, Vol. 21, Iss. 15, 2003-01 ,pp. : 1069-1079

Adis International

Access to resources Recommend Favorite

Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon

By Hesse L.M. von Moltke L.L. Greenblatt D.J.

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 513-532

Adis International

Access to resources Recommend Favorite

Coadministration of etoricoxib and warfarin is unlikely to result in clinically important interactions

Reactions Weekly, Vol. 1, Iss. 1156, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite